Pharmacovigilance – News and Features

According to a clinical trial, MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer than computed tomography-guided radiotherapy.

Scientists have created detailed structures of the human opioid receptors to guide the development of more targeted pain medications.

After a decade of research, a group of scientists has succeeded in describing a mechanism associated with the production of neuropathic pain, opening an window for the development of targeted therapies.

Children with absence epilepsy experience brief staring spells, during which they temporarily lose consciousness. Using a genetic model known as Genetic Absence Epilepsy Rats of Strasbourg (GAERS), researchers have identified the neuronal basis for this condition.

Researchers have developed an optimized genetic test for ovarian cancer, which helps accurately target an effective but expensive medication.

The US Food and Drug Administration has given a new Alzheimer’s drug the green light. The compound, lecanemab (Leqembi) is a monoclonal antibody (mAb), part of a new class of treatments that target the underlying mechanism of disease. It was approved using the FDA’s accelerated approval pathway.

One of the first studies using machine learning techniques to design drug formulations has shown promise for reducing the time and cost associated with drug development.

Researchers have developed a nanotechnology-driven solution to locally enhance T-cell functions without producing unwanted systemic side effects.

A study suggests that an unwillingness to accept a COVID-19 vaccine can be due to both a lack of concern for the consequences of contracting the virus and a lack of faith in the government’s actions.

Engineers create a device that enables intestinal organoids to develop to unprecedented levels of maturity.